WO2014131374A1 - Chaperoninas químicas como nuevos moduladores moleculares de la beta agregación proteica presente en las enfermedades conformacionales - Google Patents
Chaperoninas químicas como nuevos moduladores moleculares de la beta agregación proteica presente en las enfermedades conformacionales Download PDFInfo
- Publication number
- WO2014131374A1 WO2014131374A1 PCT/CU2013/000009 CU2013000009W WO2014131374A1 WO 2014131374 A1 WO2014131374 A1 WO 2014131374A1 CU 2013000009 W CU2013000009 W CU 2013000009W WO 2014131374 A1 WO2014131374 A1 WO 2014131374A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- chaperonins
- compounds
- salts
- fibers
- diseases
- Prior art date
Links
- 108050001186 Chaperonin Cpn60 Proteins 0.000 title claims abstract description 124
- 102000052603 Chaperonins Human genes 0.000 title claims abstract description 124
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 32
- 201000010099 disease Diseases 0.000 title claims abstract description 30
- 239000000126 substance Substances 0.000 title claims abstract description 20
- 230000002776 aggregation Effects 0.000 title description 7
- 238000004220 aggregation Methods 0.000 title description 7
- 230000006269 (delayed) early viral mRNA transcription Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 65
- 238000000034 method Methods 0.000 claims abstract description 53
- 238000011282 treatment Methods 0.000 claims abstract description 27
- 150000003839 salts Chemical class 0.000 claims abstract description 23
- 239000012453 solvate Substances 0.000 claims abstract description 19
- 239000000651 prodrug Substances 0.000 claims abstract description 16
- 229940002612 prodrug Drugs 0.000 claims abstract description 16
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical group O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 claims abstract 6
- 239000012990 dithiocarbamate Substances 0.000 claims abstract 5
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims abstract 2
- 150000001342 alkaline earth metals Chemical class 0.000 claims abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract 2
- 239000000835 fiber Substances 0.000 claims description 52
- 230000015572 biosynthetic process Effects 0.000 claims description 42
- 208000024827 Alzheimer disease Diseases 0.000 claims description 12
- 230000005764 inhibitory process Effects 0.000 claims description 12
- 206010012601 diabetes mellitus Diseases 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 208000037259 Amyloid Plaque Diseases 0.000 claims description 9
- 231100000433 cytotoxic Toxicity 0.000 claims description 9
- 230000001472 cytotoxic effect Effects 0.000 claims description 9
- -1 methyl (2-{[4-(1-naphthylamino)-4- oxobutanoyl]amino}ethyl)dithio Chemical group 0.000 claims description 7
- 230000009467 reduction Effects 0.000 claims description 7
- 238000000338 in vitro Methods 0.000 claims description 5
- 238000001727 in vivo Methods 0.000 claims description 5
- 208000024777 Prion disease Diseases 0.000 claims description 4
- 125000001624 naphthyl group Chemical group 0.000 claims description 3
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 230000010534 mechanism of action Effects 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims 2
- 229960002317 succinimide Drugs 0.000 claims 2
- XNCLPKHVNZQTDW-UHFFFAOYSA-N 6-[[4-(naphthalen-1-ylamino)-4-oxobutanoyl]amino]hexanoic acid Chemical compound C1=CC=C2C(NC(=O)CCC(=O)NCCCCCC(=O)O)=CC=CC2=C1 XNCLPKHVNZQTDW-UHFFFAOYSA-N 0.000 claims 1
- 230000001133 acceleration Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 14
- 230000001225 therapeutic effect Effects 0.000 abstract description 14
- 230000002265 prevention Effects 0.000 abstract description 9
- 102000009091 Amyloidogenic Proteins Human genes 0.000 abstract description 8
- 108010048112 Amyloidogenic Proteins Proteins 0.000 abstract description 8
- 230000003942 amyloidogenic effect Effects 0.000 abstract description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 46
- 229940098773 bovine serum albumin Drugs 0.000 description 46
- 108090000623 proteins and genes Proteins 0.000 description 40
- 235000018102 proteins Nutrition 0.000 description 39
- 102000004169 proteins and genes Human genes 0.000 description 39
- JADVWWSKYZXRGX-UHFFFAOYSA-M thioflavine T Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C1=[N+](C)C2=CC=C(C)C=C2S1 JADVWWSKYZXRGX-UHFFFAOYSA-M 0.000 description 37
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 29
- 108090000765 processed proteins & peptides Proteins 0.000 description 26
- 230000008569 process Effects 0.000 description 25
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 24
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 22
- PLOPBXQQPZYQFA-AXPWDRQUSA-N amlintide Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)CSSC1)[C@@H](C)O)C(C)C)C1=CC=CC=C1 PLOPBXQQPZYQFA-AXPWDRQUSA-N 0.000 description 21
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 20
- 239000000243 solution Substances 0.000 description 20
- 230000000670 limiting effect Effects 0.000 description 19
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 18
- 108091006905 Human Serum Albumin Proteins 0.000 description 17
- 102000008100 Human Serum Albumin Human genes 0.000 description 17
- 239000012634 fragment Substances 0.000 description 17
- 230000002401 inhibitory effect Effects 0.000 description 17
- 238000011156 evaluation Methods 0.000 description 16
- 239000000872 buffer Substances 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 13
- 102000004196 processed proteins & peptides Human genes 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 12
- 239000000203 mixture Substances 0.000 description 11
- 206010002022 amyloidosis Diseases 0.000 description 10
- 235000012754 curcumin Nutrition 0.000 description 10
- 229940109262 curcumin Drugs 0.000 description 10
- 239000004148 curcumin Substances 0.000 description 10
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 10
- 102000003952 Caspase 3 Human genes 0.000 description 9
- 108090000397 Caspase 3 Proteins 0.000 description 9
- 239000004471 Glycine Substances 0.000 description 9
- 108010006519 Molecular Chaperones Proteins 0.000 description 9
- 230000007423 decrease Effects 0.000 description 9
- 230000001681 protective effect Effects 0.000 description 9
- 102000005431 Molecular Chaperones Human genes 0.000 description 8
- 238000004113 cell culture Methods 0.000 description 8
- 230000002490 cerebral effect Effects 0.000 description 8
- 239000000178 monomer Substances 0.000 description 8
- 229920001184 polypeptide Polymers 0.000 description 8
- 230000002588 toxic effect Effects 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 230000006907 apoptotic process Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 231100000331 toxic Toxicity 0.000 description 7
- 230000002159 abnormal effect Effects 0.000 description 6
- 238000001506 fluorescence spectroscopy Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 238000001000 micrograph Methods 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 229910052700 potassium Inorganic materials 0.000 description 5
- 239000011591 potassium Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 230000035899 viability Effects 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 238000003782 apoptosis assay Methods 0.000 description 4
- 125000000751 azo group Chemical group [*]N=N[*] 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 230000001120 cytoprotective effect Effects 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000004627 transmission electron microscopy Methods 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 102000016943 Muramidase Human genes 0.000 description 3
- 108010014251 Muramidase Proteins 0.000 description 3
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- 238000003917 TEM image Methods 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 230000006933 amyloid-beta aggregation Effects 0.000 description 3
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 3
- 125000003118 aryl group Polymers 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 229960000274 lysozyme Drugs 0.000 description 3
- 235000010335 lysozyme Nutrition 0.000 description 3
- 239000004325 lysozyme Substances 0.000 description 3
- 230000000626 neurodegenerative effect Effects 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 230000004845 protein aggregation Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 230000008646 thermal stress Effects 0.000 description 3
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 2
- 208000002177 Cataract Diseases 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000004447 HSP40 Heat-Shock Proteins Human genes 0.000 description 2
- 108010042283 HSP40 Heat-Shock Proteins Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102000011782 Keratins Human genes 0.000 description 2
- 108010076876 Keratins Proteins 0.000 description 2
- 102000010445 Lactoferrin Human genes 0.000 description 2
- 108010063045 Lactoferrin Proteins 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 241000219995 Wisteria Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 229940045799 anthracyclines and related substance Drugs 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000008033 biological extinction Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 2
- 229960001076 chlorpromazine Drugs 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- TXWRERCHRDBNLG-UHFFFAOYSA-N cubane Chemical compound C12C3C4C1C1C4C3C12 TXWRERCHRDBNLG-UHFFFAOYSA-N 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
- VFPFQHQNJCMNBZ-UHFFFAOYSA-N ethyl gallate Chemical compound CCOC(=O)C1=CC(O)=C(O)C(O)=C1 VFPFQHQNJCMNBZ-UHFFFAOYSA-N 0.000 description 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 2
- 229940078795 lactoferrin Drugs 0.000 description 2
- 235000021242 lactoferrin Nutrition 0.000 description 2
- 238000010150 least significant difference test Methods 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229960000901 mepacrine Drugs 0.000 description 2
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 2
- 229960002009 naproxen Drugs 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 2
- 230000007310 pathophysiology Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 108010040003 polyglutamine Proteins 0.000 description 2
- 230000005522 programmed cell death Effects 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 2
- GPKJTRJOBQGKQK-UHFFFAOYSA-N quinacrine Chemical compound C1=C(OC)C=C2C(NC(C)CCCN(CC)CC)=C(C=CC(Cl)=C3)C3=NC2=C1 GPKJTRJOBQGKQK-UHFFFAOYSA-N 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 102000013498 tau Proteins Human genes 0.000 description 2
- 108010026424 tau Proteins Proteins 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000002753 trypsin inhibitor Substances 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- XEDWWPGWIXPVRQ-UHFFFAOYSA-N (2,3,4-trihydroxyphenyl)-(3,4,5-trihydroxyphenyl)methanone Chemical compound OC1=C(O)C(O)=CC=C1C(=O)C1=CC(O)=C(O)C(O)=C1 XEDWWPGWIXPVRQ-UHFFFAOYSA-N 0.000 description 1
- AAWZDTNXLSGCEK-LNVDRNJUSA-N (3r,5r)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid Chemical compound O[C@@H]1CC(O)(C(O)=O)C[C@@H](O)C1O AAWZDTNXLSGCEK-LNVDRNJUSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- QHSYXMARPLFYEN-UHFFFAOYSA-N 1-amino-6-hydroxyhexane-1-sulfonic acid Chemical compound OCCCCCC(S(=O)(=O)O)N QHSYXMARPLFYEN-UHFFFAOYSA-N 0.000 description 1
- NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 description 1
- CCUWGJDGLACFQT-UHFFFAOYSA-N 2,2,3,3,4,4-hexafluoropentanedioic acid Chemical compound OC(=O)C(F)(F)C(F)(F)C(F)(F)C(O)=O CCUWGJDGLACFQT-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- KWNBVCKOPJXOIC-UHFFFAOYSA-N 2-morpholin-4-yl-1h-pyrimidin-6-one Chemical compound OC1=CC=NC(N2CCOCC2)=N1 KWNBVCKOPJXOIC-UHFFFAOYSA-N 0.000 description 1
- DSIHEWRAJBNNLQ-UHFFFAOYSA-N 3-(4-phenyl-3,6-dihydro-2h-pyridin-1-yl)propane-1-sulfonic acid Chemical compound C1N(CCCS(=O)(=O)O)CCC(C=2C=CC=CC=2)=C1 DSIHEWRAJBNNLQ-UHFFFAOYSA-N 0.000 description 1
- GYJNVSAUBGJVLV-UHFFFAOYSA-N 3-(dimethylazaniumyl)propane-1-sulfonate Chemical compound CN(C)CCCS(O)(=O)=O GYJNVSAUBGJVLV-UHFFFAOYSA-N 0.000 description 1
- RJCHCFQTUKAYAA-UHFFFAOYSA-N 5-[[2-amino-5-[(4-methoxyphenyl)methyl]-3-methylimidazol-4-yl]methyl]-2-methoxybenzene-1,3-diol Chemical compound C1=CC(OC)=CC=C1CC1=C(CC=2C=C(O)C(OC)=C(O)C=2)N(C)C(=N)N1 RJCHCFQTUKAYAA-UHFFFAOYSA-N 0.000 description 1
- FQWUNUXAOHTLLG-ASDGIDEWSA-N 6-[(3s,6s,9s,12r)-3,6-dibenzyl-2,5,8,11-tetraoxo-1,4,7,10-tetrazabicyclo[10.3.0]pentadecan-9-yl]-n-hydroxyhexanamide Chemical compound C([C@H]1C(=O)N2CCC[C@@H]2C(=O)N[C@H](C(N[C@@H](CC=2C=CC=CC=2)C(=O)N1)=O)CCCCCC(=O)NO)C1=CC=CC=C1 FQWUNUXAOHTLLG-ASDGIDEWSA-N 0.000 description 1
- 102100038222 60 kDa heat shock protein, mitochondrial Human genes 0.000 description 1
- AFPQUGBYSAOVCN-UHFFFAOYSA-N 8-methoxyquinoline-5-sulfonic acid Chemical compound C1=CN=C2C(OC)=CC=C(S(O)(=O)=O)C2=C1 AFPQUGBYSAOVCN-UHFFFAOYSA-N 0.000 description 1
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 1
- 229920003026 Acene Polymers 0.000 description 1
- 102100026882 Alpha-synuclein Human genes 0.000 description 1
- 102100034452 Alternative prion protein Human genes 0.000 description 1
- 102000001049 Amyloid Human genes 0.000 description 1
- 108010094108 Amyloid Proteins 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 102100032187 Androgen receptor Human genes 0.000 description 1
- 208000028185 Angioedema Diseases 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- 101710081722 Antitrypsin Proteins 0.000 description 1
- 108010059886 Apolipoprotein A-I Proteins 0.000 description 1
- 102000005666 Apolipoprotein A-I Human genes 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 102000011899 Aquaporin 2 Human genes 0.000 description 1
- 108010036221 Aquaporin 2 Proteins 0.000 description 1
- 102000014461 Ataxins Human genes 0.000 description 1
- 108010078286 Ataxins Proteins 0.000 description 1
- 101800001288 Atrial natriuretic factor Proteins 0.000 description 1
- 102400001282 Atrial natriuretic peptide Human genes 0.000 description 1
- 101800001890 Atrial natriuretic peptide Proteins 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 1
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 1
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 201000007120 C1 inhibitor deficiency Diseases 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 101100507655 Canis lupus familiaris HSPA1 gene Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010008025 Cerebellar ataxia Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 108010058432 Chaperonin 60 Proteins 0.000 description 1
- 102000055157 Complement C1 Inhibitor Human genes 0.000 description 1
- 108700040183 Complement C1 Inhibitor Proteins 0.000 description 1
- AAWZDTNXLSGCEK-UHFFFAOYSA-N Cordycepinsaeure Natural products OC1CC(O)(C(O)=O)CC(O)C1O AAWZDTNXLSGCEK-UHFFFAOYSA-N 0.000 description 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 206010011659 Cutaneous amyloidosis Diseases 0.000 description 1
- 102000012192 Cystatin C Human genes 0.000 description 1
- 108010061642 Cystatin C Proteins 0.000 description 1
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 description 1
- 102100023419 Cystic fibrosis transmembrane conductance regulator Human genes 0.000 description 1
- 244000309456 Decussocarpus nagi Species 0.000 description 1
- 235000008375 Decussocarpus nagi Nutrition 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 1
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 1
- 229920002079 Ellagic acid Polymers 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 239000004262 Ethyl gallate Substances 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 208000034846 Familial Amyloid Neuropathies Diseases 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 102000004878 Gelsolin Human genes 0.000 description 1
- 108090001064 Gelsolin Proteins 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 102000053171 Glial Fibrillary Acidic Human genes 0.000 description 1
- 108700005000 Glial Fibrillary Acidic Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010019860 Hereditary angioedema Diseases 0.000 description 1
- 206010019889 Hereditary neuropathic amyloidosis Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- 208000001826 Marfan syndrome Diseases 0.000 description 1
- 208000037196 Medullary thyroid carcinoma Diseases 0.000 description 1
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 101100189870 Mus musculus Pga5 gene Proteins 0.000 description 1
- IKMDFBPHZNJCSN-UHFFFAOYSA-N Myricetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC(O)=C(O)C(O)=C1 IKMDFBPHZNJCSN-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-L O-phosphonato-L-serine(2-) Chemical compound [O-]C(=O)[C@@H]([NH3+])COP([O-])([O-])=O BZQFBWGGLXLEPQ-REOHCLBHSA-L 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 108010069013 Phenylalanine Hydroxylase Proteins 0.000 description 1
- 102100038223 Phenylalanine-4-hydroxylase Human genes 0.000 description 1
- 201000011252 Phenylketonuria Diseases 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical group OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- 108010071690 Prealbumin Proteins 0.000 description 1
- 102000007584 Prealbumin Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- AAWZDTNXLSGCEK-ZHQZDSKASA-N Quinic acid Natural products O[C@H]1CC(O)(C(O)=O)C[C@H](O)C1O AAWZDTNXLSGCEK-ZHQZDSKASA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
- 102100040756 Rhodopsin Human genes 0.000 description 1
- 108090000820 Rhodopsin Proteins 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 102400000827 Saposin-D Human genes 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- 102000054727 Serum Amyloid A Human genes 0.000 description 1
- 108700028909 Serum Amyloid A Proteins 0.000 description 1
- 108010021188 Superoxide Dismutase-1 Proteins 0.000 description 1
- 102100038836 Superoxide dismutase [Cu-Zn] Human genes 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
- 102000004136 Vasopressin Receptors Human genes 0.000 description 1
- 108090000643 Vasopressin Receptors Proteins 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000005466 alkylenyl group Chemical group 0.000 description 1
- 108090000185 alpha-Synuclein Proteins 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 230000001475 anti-trypsic effect Effects 0.000 description 1
- 239000004019 antithrombin Substances 0.000 description 1
- 108010073614 apolipoprotein A-IV Proteins 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 description 1
- 239000000987 azo dye Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- GEHJBWKLJVFKPS-UHFFFAOYSA-N bromochloroacetic acid Chemical compound OC(=O)C(Cl)Br GEHJBWKLJVFKPS-UHFFFAOYSA-N 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 229960003530 donepezil Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 229960002852 ellagic acid Drugs 0.000 description 1
- 235000004132 ellagic acid Nutrition 0.000 description 1
- 230000005183 environmental health Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 1
- 230000001667 episodic effect Effects 0.000 description 1
- 235000019277 ethyl gallate Nutrition 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 229950006404 exifone Drugs 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229960003980 galantamine Drugs 0.000 description 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- PPHTXRNHTVLQED-UHFFFAOYSA-N lixivaptan Chemical compound CC1=CC=C(F)C=C1C(=O)NC(C=C1Cl)=CC=C1C(=O)N1C2=CC=CC=C2CN2C=CC=C2C1 PPHTXRNHTVLQED-UHFFFAOYSA-N 0.000 description 1
- 239000003580 lung surfactant Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000031852 maintenance of location in cell Effects 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 201000000083 maturity-onset diabetes of the young type 1 Diseases 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 1
- LXBIFEVIBLOUGU-DPYQTVNSSA-N migalastat Chemical compound OC[C@H]1NC[C@H](O)[C@@H](O)[C@H]1O LXBIFEVIBLOUGU-DPYQTVNSSA-N 0.000 description 1
- 229950007469 migalastat Drugs 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- PCOBUQBNVYZTBU-UHFFFAOYSA-N myricetin Natural products OC1=C(O)C(O)=CC(C=2OC3=CC(O)=C(O)C(O)=C3C(=O)C=2)=C1 PCOBUQBNVYZTBU-UHFFFAOYSA-N 0.000 description 1
- 235000007743 myricetin Nutrition 0.000 description 1
- 229940116852 myricetin Drugs 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- QKXJWFOKVQWEDZ-UHFFFAOYSA-N n-tert-butyl-4-[5'-ethoxy-4-(2-morpholin-4-ylethoxy)-2'-oxospiro[cyclohexane-1,3'-indole]-1'-yl]sulfonyl-3-methoxybenzamide Chemical compound C12=CC(OCC)=CC=C2N(S(=O)(=O)C=2C(=CC(=CC=2)C(=O)NC(C)(C)C)OC)C(=O)C1(CC1)CCC1OCCN1CCOCC1 QKXJWFOKVQWEDZ-UHFFFAOYSA-N 0.000 description 1
- 229930189110 naamine Natural products 0.000 description 1
- 150000002790 naphthalenes Chemical class 0.000 description 1
- 150000005209 naphthoic acids Chemical class 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000004963 pathophysiological condition Effects 0.000 description 1
- 230000006919 peptide aggregation Effects 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000008196 pharmacological composition Substances 0.000 description 1
- 150000002990 phenothiazines Chemical class 0.000 description 1
- 229950009215 phenylbutanoic acid Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Substances OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 1
- YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 description 1
- 229960001237 podophyllotoxin Drugs 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000007824 polyneuropathy Effects 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 208000030153 prolactin-producing pituitary gland adenoma Diseases 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 229940079877 pyrogallol Drugs 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940124598 therapeutic candidate Drugs 0.000 description 1
- 208000013818 thyroid gland medullary carcinoma Diseases 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 201000007905 transthyretin amyloidosis Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Definitions
- alkyl and alkyl refer to linear or branched aliphatic chains of saturated and hydrogen carbon atoms, preferably 1 to 4 carbon atoms, comprised between the methyl, ethyl, / 7-propyl, / ' so-propyl groups , n-butyl or / so-butyl.
- alkylenyl refers to divalent analogs of linear or branched alkyl groups, preferably ethynyl (-CH 2 CH 2 -) or butynyl (-CH 2 CH 2 CH 2 CH 2 -) radicals.
- the present invention provides a new method of prevention and therapeutic treatment of CDs, by inhibition, reduction, disaggregation of (as prefibrillar structures, protofibrils, fibers and amyloid plaques, all characterized by presenting ⁇ -crossed toxic structures (eg. Disease Alzheimer's disease (AD), Parkinson's disease (PD), Type 2 Diabetes Mellitus (DM2), among others), through the administration of the compounds of Formula I, considered in this invention as chemical chaperonins, in any acceptable pharmaceutical composition of one or more compounds or their salts, prodrug or solvate, which are capable of inhibiting, reducing, eliminating, etc., the formation of these structures that cause an abnormal folding of the proteins, as well as the disaggregation of the already formed fibers.
- ⁇ -crossed toxic structures eg. Disease Alzheimer's disease (AD), Parkinson's disease (PD), Type 2 Diabetes Mellitus (DM2), among others
- AD Alzheimer's disease
- PD Parkinson's disease
- DM2 Type 2 Diabetes Mel
- This invention relates to Chemistry and Biochemistry applied to the field of medicine and relates to a new method to inhibit, reduce or prevent the formation of ⁇ -crossed toxic structures: prefibrils, protofibrils, fibers and amyloid plaques present in the Diseases Conformational (EC) (Table 1) and in particular those of amioid origin, through the administration of one or several compounds of Formula I, considered as chemical chaperonins, capable of inhibiting, reducing, disaggregating, refolding and preventing, among others, formation of the aforementioned structures.
- EC Diseases Conformational
- these proteins can form oligomers and protofibrils that will give rise to the fibers that, depending on the affected organ and the cytotoxicity of each of these structures, promote the late or episodic appearance of these diseases.
- Carrell, R. W. and Lomas, D. A. Lancet, 1997, 350, 134-138 More than 15 proteins that can form these amyloid fibrils clearly associated with various pathological conditions have been reported.
- Table 1 shows a non-exhaustive list of several CDs together with their white protein.
- Cystatin C Hereditary cerebral angiopathy
- Rhodopsin Retinitis pigmentosa Rhodopsin Retinitis pigmentosa
- the oligomers have been reported to be toxic at the cellular level, regardless of the amioid protein from which they are formed. This shows that this cytotoxic effect has a common molecular mechanism in all cases.
- amyloid proteins The predominant structure of amyloid proteins is the ⁇ -cross lamina. This structure remains stable in protein aggregation and oligomerization, which explains the entrenchment and deposition of amyloid aggregates in various organs causing tissue damage and organic dysfunction (Yanker BA et al. Science 1990, 250, 279-282; Lorenzo A. and col. Nature 1994, 368, 756-760; O'Brien TD et al. T. n. J. Pathol. 1995, 147, 609-616; Pike Ch. J. et al. Brain Res. 1991,
- ⁇ -cross sheets The formation of ⁇ -cross sheets is caused by multiple pathophysiological conditions that trigger the production of these structures. Among these factors are the alteration of the physicochemical properties of the
- DM2 is a metabolic disease characterized by the progressive death of pancreatic ⁇ cells, the deposition of cytotoxic amyloid amyloid fibers in white tissue and insulin resistance.
- Amylin also known as IAPP, is a 37 amino acid peptide secreted along with insulin.
- AD is characterized by the presence in the brain of neurofibrillar lattices and senile plaques. These neuropathological deposits are involved in the process that leads to progressive degeneration and neuronal death.
- Senile plaques are located in the extracellular space of neurons and are mainly formed by deposits of ⁇ -amyloid ( ⁇ ) peptides, between 39 and 42 amino acids.
- D SO dimethylsulfoxide
- NOV V-octyl-h-valienamine
- N-alkylated deoxynorjirimycin 4-phenylbutyric acid
- anthracyclines porphyrins and azo compounds, among others.
- WO 03/063880 provides a methodology to block the toxicity of amyloid proteins in cells with the use of one or more polycyclic compounds. Among them, preferably polyacenes, substituted or not, containing three or four rings.
- this invention relates to the methods of irruption of the transition from amylin (IAPP) from its native soluble state to the oligomeric and / or insoluble fibrillar state, as well as the inhibition of pre or protofibrillar amyloid aggregates and fibers. These compounds also decrease the production of amyloid proteins so that they can be used in the prevention and treatment of pancreatic amyloidosis.
- a treatment method for DM2 is specifically described.
- quinacrine is quinacrine
- chlorpromazine is acridine
- phenothiazines is acridine
- anthracyclines is acridine
- quinacrines is acridine
- chlorpromazine is acridine
- Congo Red RC
- Watanabe K. et al in US 8, 106,045B2 state that polycyclic compounds of the type 2-morpholino-4-pyrimidone and its derivatives may be effective for the prevention and treatment of AD caused by the hyperactivity of the tau protein , claiming the action of these compounds against the structures amyloid present in other neurodegenerative pathologies, DM2 and certain neoplastic.
- myricetin exifone, pyrogallol, tannic acid, pyrocatechol, quercetin, ellagic acid, 1,2,4-benzenethriol, 5- hydroxidepamine, gallamide trihydrate, gallic acid, ethyl gallate and quinic acid among others.
- this invention provides a method and the pharmacology composition for the treatment of amyloidosis.
- Other types of molecules that specifically bind to the deposits of the insoluble amyloid protein are those derived from styrylbenzenes ⁇ Zhuang et al. in J. Med. Chem., 2001, 44, 12, 1905-14) and pyridine (Kung et al. in Mol. Imaging Bioi, 2003; 5, 6, 418-26).
- the stilbenzene derivatives shown by Kung et al. in WO 03018070 and in WO 2006066104 they have been effective as inhibitors of amyloid aggregation.
- pamoic acid is a derivative of naphthoic acid that has two naphthyl groups in its structure.
- Minetti et al. in WO 2007045593 describe other naphthyl derivatives that also inhibit amyloid aggregation and which according to their inventors cross the BHE.
- Hays et al. in WO 9716194 they describe some naphthyl-azo compounds, which also inhibit amyloid aggregation and can be used in pharmaceutical compositions to treat the pathologies derived from these structures.
- the Food and Drug Administration of the United States of America has approved the use of donepezil, rivastigm / na or galantamine, however these drugs do not stop the evolution or reinvest the neurodegenerative process of EA and are only temporarily effective for a few months or a few years.
- the present invention provides a new method of prevention and therapeutic treatment of CDs and in particular those of amyloid origin, through the inhibition, reduction, disaggregation of prefibrillar structures, protofibrils, fibers and plaques, all characterized by presenting toxic structures.
- These compounds can be used in any acceptable pharmaceutical composition and administered by different routes, as monotherapy or in combination of one or more compounds, their salts, prodrugs or solvates that are capable of inhibiting, reducing, eliminating or disaggregating among others, these originated structures. by an abnormal folding of proteins. These compounds could also be administered to completely reverse the formation of said fibers.
- the extension of this invention includes the treatment of diseases susceptible to benefit from the biological activities shown by the compounds described in the present invention, or of a pharmaceutically acceptable salt, derivative, prodrug or solvate thereof.
- derivative includes both pharmaceutically acceptable compounds, that is, derivatives of the compounds of Formula I that can be used in the manufacture of a medicament, as well as pharmaceutically acceptable derivatives, since these could be useful in the preparation of pharmaceutically acceptable derivatives.
- prodrug includes any compound derived from a compound of Formula I, for example, esters, including carboxylic acid esters, amino acid esters, phosphate esters, metal salt sulphonate esters, carbamates , amides, without being limited to these examples, which, when administered to an individual, is capable of providing, directly or indirectly, said compound of Formula I.
- said derivative is a compound that increases the bioavailability of the compound of
- the compounds of the invention may be in crystalline form as free compounds or as solvates and it is intended that both forms are within the scope of the present invention.
- the term "solvate”, as used herein, includes both pharmaceutically acceptable solvates, that is, solvates of the compounds of Formula I that can be used in the manufacture of a medicament, such as pharmaceutically acceptable solvates, which may be useful in the preparation of pharmaceutically acceptable solvates or salts.
- the compounds of Formula I, their isomers, salts, prodrugs or solvates will preferably be found in a pharmaceutically acceptable or substantially pure form, that is, having a pharmaceutically acceptable level of purity excluding additives.
- the purity levels for the active ingredient are preferably greater than 90%. In a preferred embodiment, they are greater than 95% of the compounds of Formula I, or their salts, solvates or prodrugs.
- the compounds of the invention can be used together with other additional drugs to provide a combination therapy.
- Said additional drugs may be part of the same pharmaceutical composition or alternatively, they may be provided in the form of a separate composition for simultaneous or non-simultaneous administration to the pharmaceutical composition comprising one or more compounds of Formula I or a prodrug, solvate. , derivative or a pharmaceutically acceptable salt thereof.
- the term "effective amount” refers to the amount of the agent or compound capable of developing the therapeutic action determined by its pharmacological properties, calculated for
- the patient's clinical data such as age, state of! patient, the severity of the disorder or disorder, and the route and frequency of administration.
- Amyloidegenic protein It refers to any polypeptide.
- polypeptides include those that are relevant in medicine or biotechnology such as antibodies, insulin, amylin, ⁇ -amyloid peptide, toxins, hormones, etc. (Table 1)
- the first is one in which the polypeptide to be refolded is in an unfolded or abnormally folded state or both. In this case, the correct refolding is promoted by the method of invention.
- the misfolded peptide is already forming protofibrils and / or amyloid fibers and in this case the method of the invention serves to reduce and / or inhibit the formation of protofibrils and amyloid fibers or to disaggregate and destroy the already formed fibers.
- Chemical chaperonin In general it is a chemical compound of low molecular weight, without this being a limitation in its definition, which participates in the promotion of the folding of proteins in a non-enzymatic way, and avoids anomalous conformations facilitating the structural alignment of the polypeptide and correcting anomalies in the process. It binds to polypeptides that are unstable or in a non-native structural state or with an incorrect secondary or tertiary structure.
- These chemical chaperonins include the compounds of Formula I.
- Aggregation refers to the polymerization of misfolded oligomers that have the ability to form interactions with each other.
- Amyloidogenic which has the property of forming fibers with ⁇ -cross structures.
- Apoptosis It is a process of programmed cell death, in which the cell destroys itself in order to prevent the progression of damage both locally and tissue.
- BHC Blood-brain barrier
- Therapeutic Targets Organ, tissue, cell, receptor, gene, protein, or others, which are the therapeutic target or the center of attack of a certain treatment.
- Cytotoxic It is any compound that has the power to interfere with normal cellular processes, causing damage and sometimes cell death.
- Conformation It is the three-dimensional structure that a chemical compound adopts in relation to the rotation that occurs through one or more simple covalent bonds.
- Functional conformation refers to the structure of a protein, in which it can carry out all the functions for which it is designed.
- Cellular Control They are the cell's own mechanisms that have as their objective the maintenance of the integrity of the cell and its environment.
- Naphthalene derivatives They are those substances chemically similar to a parent substance.
- Naphthalene derivatives They are those chemical compounds that contain an aromatic bicyclic group equal to that of naphthalene in its structure. In this document, refer to derivatives of Formula I.
- Conformational Diseases They are the set of diseases whose pathophysiology is based on the accumulation of fibers and the formation of toxic oligomers of a peptide or misfolded protein of ⁇ -cross conformation (Table 1).
- Thermal stress refers to the phenomenon in which cell damage occurs due to exposure to temperatures higher than optimal. Enzymes and proteins are affected during thermal stress, causing damage to the cellular machinery and in some cases cell death.
- Glycosylation or glycosylation implies the conjugation of both terminal and lateral amino groups with molecules with mono, di and oligosaccharides.
- Inhibition It refers to a decrease in normal activity. In the case of the present, it refers to the decrease in the kinetics of aggregation of peptides and proteins due to the presence of a compound.
- Modulation It refers to the intervention of chaperonins in the aggregation process of misfolded peptides. It can be positive or negative modulation. Modulator It refers to the compounds of Formula I capable of inhibiting, reducing, eliminating and disaggregating the structures that cause an abnormal folding of the proteins.
- Monotherapy It is the administration of a single substance to combat a pathology.
- Neurodegenerative A process is said to be neurodegenerative when it causes chronic death or neuronal malfunction.
- Oligomer They are soluble aggregates of high molecular weight.
- Amyloid Peptide It refers to fibrous and insoluble aggregates that share several characteristics, among which is a high content of domains in the form of ⁇ -cross-laminate.
- Senile plates They are aggregates of amyloid proteins on the outside of neurons.
- Prefibrillate It is said of those aggregated and soluble oligomers that have not formed fibers.
- Prodrug are substances, which can be transformed in the body into a drug with therapeutic activity.
- Protofibrils are peptide oligomers that when interacting with other similar oligomers can give rise to fibers.
- Figure 1 The structures and IUPAC name of the selected compounds are presented, as non-limiting examples of Formula I, whose evaluations are exemplified, as well as of the reference compounds used (naproxen and curcumin).
- FIG. 2 Transmission electron micrographs of the fibrogenesis process of Human Serum Albumin (HSA) (3,017 ⁇ ) in the presence of chaperonin A (3,017 ⁇ and 9,051 ⁇ ) are shown. Incubated at 65 ° C for 72 hrs in Tris (pH 7.4; 20 mM).
- HSA Human Serum Albumin
- BSA Bovine Serum Albumin
- FIG. 5 Fluorescence Electron Microscopy images of the BSA fibrinogenesis process (100 ⁇ 100) are shown in the presence or absence of the
- Figure 10 The kinetics of fibril formation of fragment 20-29 of the IAPP (100 ⁇ ) at 25 ° C in PBS (pH 7.4; 100 mM; 100 mM NaCI) in the presence or absence of chaperonins A, B, are presented.
- C, D, E, and F 100 ⁇
- Part A of the figure and the inhibitory effect of the formation of fibrils by their action chaperonins LAPP.ThT molar ratio of 50: 1.
- Figure 11 the effect of chaperonin B concentration (molar ratios of lAPP: Chap B: 1: 0.5; 1: 1, 1.5), selected as a non-limiting example of Formula I, on the kinetics of formation of fibrils of the 20-29 fragment of lAPP (100 ⁇ ) at 25 ° C in PBS (pH 7.4; 100 mM; 100 mM NaCI).
- Figure 12 the evaluation of the cell viability of cerebellar Granular Cell (CGC) cell cultures of rats, exposed to fragments of lAPP (fragment 20-29 of lAPP: monomer not added and aggregated), in the presence or absence of Chaperonins B and D, selected as non-limiting examples of Formula I.
- FIG 13 The evaluation of cell apoptosis of Cerebellar Granular Cell (CGC) cell cultures exposed to lAPP fragments (fragment 20-29 of lAPP: monomer not added and aggregated) is presented, in the presence or absence of chaperonins B and D, selected as non-limiting examples of Formula I.
- Reference compound Curcumin.
- Figure 14 The evaluation of the protective and / or reconditioning activity of chaperonins B, C and D is presented, as non-limiting examples of Formula I, when administered to Cerebellar Granular Cell (CGC) cultures, which in unison are subjected to a medium low in potassium, -KCI. Part A of the figure presents the results with respect to the control of -KCI (protective effect) and part B of the figure presents the results with respect to the control of standard potassium + KCI (reconditioning effect).
- Figure 15 The evaluation of the protective and / or reconditioning activity of chaperonins B, C and D is presented, when administered to Cerebellar Granular Cell (CGC) cultures 4 h after they were exposed to a culture medium low potassium (-KCI). Part A of the figure presents the results with respect to -KCI (protective effect) and part B of the figure presents
- Example 1 Evaluation of the chaperonin modulator character in the formation of HSA fibers by transmission electron microscopy (TEM).
- the HSA solution (5 ⁇ ) is placed on 300 mesh copper gratings coated with formvar for 3 minutes. Excess solution is removed with micropipette. Subsequently, uranyl acetate (5 pL, 2%) is added, previously centrifuged at 12000 rpm for 10 minutes. The excess contrast is removed after 2 min. and the louvers are air dried for sufficient time.
- the observation and recording of the samples is carried out using a Jeol microscope model JEM-1010 operated at 80 keV and coupled to an MTI digital camera model CCD-300-RC.
- Figure 2 shows that in the absence of chaperonins, abundant long, contoured HSA fibers are produced after 48 hours. In contrast, in the presence of chaperonin A, the fibers are very small and short. Likewise, it is observed that at a higher concentration of chaperonin A the fibers practically disappear and only oligomers are observed, whereby the inhibitory character of chaperonin A is inferred.
- Example 2. Evaluation of the modulating capacity of chaperonins in the formation of human serum albumin fibers (HSA).
- Th-T Thioflavin-T (ThT): Th-T (Sigma, 47 mg) is dissolved in water and made up to a final volume of 25 mL.
- Chaperonin The selected chaperonin is dissolved, as a non-limiting example of Formula I, (75.4 pmol; A, B, C, D, figure 1) in 25 mL of DMSO.
- IF fluorescence intensity
- Example 3 Evaluation of the modulatory character of the chaperonins in the kinetics of bovine serum albumin fiber (BSA), by fluorescence spectroscopy. Preparation of study solutions.
- BSA bovine serum albumin fiber
- Thioflavin-T Th-T ⁇ Sigma, 10 mg is dissolved in water and made up to a final volume of 5 mL.
- Chaperonin The selected chaperonin is dissolved, as a non-limiting example of Formula I, (75.4 ⁇ ; A; B, C, D, E, F and G, figure 1) in 1.2 mL of DMSO and flush to a final volume 10 mL with the buffer.
- the BSA fibrinogenesis process did not present a well-defined lag phase and stabilized after 120 min. approximately.
- IF fluorescence intensity
- Example 4. Evaluation of the modulatory character of the chaperonins in the formation of BSA fibers by fluorescence microscopy.
- Sample preparation is carried out in a similar way to that described in Example 3.
- the plate is incubated at 65 ° C for 3 h., Then 100 pL of sample is deposited in an eppendorf tube and ThT is added to reach a final concentration. of 20 ⁇ .
- the samples were centrifuged at 1300rpm, for 2 minutes. 6 pL of sample are deposited on a slide with its coverslip. They are observed through the Zeiss Axiostar plus fluorescence microscope, with HBO 50 / AC lamp, with blue filter. The images are registered at 10x.
- Example 5 Evaluation of the chaperonin modulating character in the fiber formation kinetics of BSA, by fluorescence spectroscopy.
- ThT Thioflavin T
- Chaperonin The selected chaperonin is dissolved as a non-limiting example of Formula I (75.4 pmol: A, B, C, D, E, F and G, figure 1) in DMSO and is flush to a final volume of 10 mL with the selected buffer.
- BSA solutions (BSA in the absence of chaperonin at 50 ⁇ ) and mixtures of BSA at the same concentration with chaperonins (molar ratios of BSA: chaperonin: 1: 0; 1: 0.0025; 1: 0.005; 1: 0.01; 1 : 0.02; 1: 0.1; 1: 1; 1: 2) are passed through syringe filters of the acrodisk type with 0.2 ⁇ pore (Sigma-Aldrich). These solutions are incubated at a temperature between 20 and 75 ° C, without stirring.
- ThT 10mg / mL
- ThT 10mg / mL
- the table with the IC50 values, obtained for each inhibitor evaluated is shown as a non-limiting example.
- the calculation is carried out through the interpolation of the data by means of a logarithmic function. It is found that aggregation inhibitory activity is dependent on the concentration of the chaperonins.
- the inhibitory activity of chaperonins A and B are similar to each other and twice higher than C.
- chaperonin D was 17 times higher than the previous ones.
- Example 6 Evaluation of the modulating character of tas chaperonins in the formation of BSA fibers by transmission electron microscopy ⁇ ).
- Example 7 Evaluation of the chaperonin modulating character in the fiber formation kinetics of IAPP (20-29 aa by fluorescence spectroscopy.
- ThT Thioflavin T
- IAPP fragment 20-29 of IAPP is synthesized according to the procedure described (Kates, E. and Albericio, F. in Solid-Phase Synthesis; Marcel Dekker Inc .: New York, 2000; Hood, CA; et al. Pepf. Sci. 2008, 14, 97-101).
- SP-HPLC high resolution semipreparative Reverse Chromatography
- MM 1029 Da
- ESI-MS mass spectrometry
- Chaperonin The selected chaperonin is dissolved as a non-limiting example of Formula I (75.4 ⁇ ) in 1.2 mL of DMSO and flush to a final volume of 10 mL with the buffer (PBS, pH 7.4, 100 mM; NaC1 00 mM) .
- the buffer PBS, pH 7.4, 100 mM; NaC1 00 mM
- the IAPP solution (20-29, 100 ⁇ ) without and with chaperonins (100 ⁇ ) is incubated at 25 ° C in methacrylate cells (Sigma-Aldrich) volume 4.5 mL, optical path 10 mm, in the presence of ThT (20 ⁇ ) at an IAPP: ThT molar ratio of 50: 1 and stirred during kinetics.
- the IF Cary Eclipse spectrofluorometer
- All signals are corrected with the background signal, for which a blank containing ThT in water is prepared, in the absence of protein.
- Figure 10 shows the modulating effect of chaperonins A, B, C, D, E and F on the formation of fibrils of fragment 20-29 of the IAPP at 25 ° C. All the chaperonins modulated this process at the concentration evaluated (molar ratio peptide: chap 1: 1). Chaperonins E and F accelerated the formation of IAPP fibers. In contrast, chaperonins A, B, C and D increased the average time of fiber formation, that is, delayed the fibrinogenesis process ( Figure 10, Part B). In the case of chaperonin B, this inhibitory behavior was maintained for protein.chaperonin molar ratios less than or equal to 1: 1 ( Figure 1 1). On the other hand, when the molar ratio is higher, the process was accelerated and the concentration of fibers formed increased.
- Example 8 Evaluation of the cellular viability of cerebellar granular cells (CGC) in the presence of IAPP 20-29 (monomer and aggregate). Cytoprotective effect of chaperonins.
- Chaperonin Solutions are prepared in 1.2 mL of DMSO and made up to a final volume of 10 mL with the buffer of chaperonin B and D (25 ⁇ ), selected as non-limiting examples of Formula I.
- curcumin 5.5 mM prepared in ethanol is used.
- the viability of the CGC cell cultures was evaluated with fragment 20-29 of the IAPP, in its mono-American and aggregate form or with mixtures of protein chaperonin at different molar ratios.
- fragment 20-29 of the IAPP in its mono-American and aggregate form or with mixtures of protein chaperonin at different molar ratios.
- curcumin acts as a potent cytoprotector when cells are exposed to proteins in aggregate form and do not exert this function against monomeric ones.
- the novel cytoprotective effect of the chaperonins evaluated on the CGCs in the presence of the cytotoxic monomer of the IAPP could be explained through a mechanism of action of the type: inhibition of aggregation, reduction of aggregation or elimination of the monomer, among others.
- Example 9 Evaluation of the apoptotic effect of fragments of IAPP 20-29 (monomer and aggregate) and chaperonins on cerebellar granular cells (CGC).
- the solutions of chaperonins B and D are prepared at 25 ⁇ each, in DMSO and curcumin (5.5 ⁇ ) in ethanol.
- the apoptotic effect of proteins and the cytoprotective effect of chaperonins B and D, selected as non-limiting examples of Formula I, are evaluated in CGC cell cultures and curcumin is used as the reference compound. Briefly, in all the samples half of its volume is extracted from the culture medium to add, independently, the corresponding amounts of test protein (IAPP, in its mono-American and aggregate form), protein mixtures: chaperonins at different molar ratios ( 1: 0.3 or 1: 1) or chaperonins. Then, the enriched medium is reincorporated into the cell culture and again, incubated for 4 h. additional. Cellular apoptosis is estimated by immunofluorescent determination of caspase-3 levels (J.
- chaperonins B, C and D selected as non-limiting examples of Formula I, are evaluated in CGC cultures at low concentrations of potassium (-KCI).
- the culture medium of the wells with 25 mM KCI (+ KCI) is removed by aspiration and replaced by a -KCI medium (5 mM).
- Chaperonins B, C and D are added separately, at the initial time (Group I) or after 4 h. (Group II) of induction of the pro-apoptotic stimulus (-KCI) and incubate 4 h. additional, including the two control groups: -KCI and + KCI.
- Apoptosis is estimated by immunofluorescent determination of caspase-3 levels (J. Morán et al. In J. Neurochem. 1999, 73, 2, 568-77), using the Synergy-Bioteck spectrofluorometer.
- Figure 14 shows a reduction in caspase-3 levels in the Group I CGCs with respect to the control group -KCI. This reduction was 92, 80 and 78% for samples treated with B, C and D, respectively (Part A, figure 14). On the other hand, caspase-3 levels (Part B, figure 14) for samples with chaperonins B, C and D of Group I were lower by 84, 54 and 52%, respectively, in relation to the Control Group + KCI. These results show the protective effect of the chaperonins evaluated with respect to both controls.
- Figure 15 shows that in Group II, the caspase-3 level was lower for the samples treated with chaperonins B, C and D (56%, 66% and 26%, respectively) with respect to to the Control Group -KCI, so a protective effect is evident.
- this level of caspase-3 is compared with that of the + KCI control ( Figure 5, Part B) it is observed that in the case of chaperonins B and C there are no appreciable differences.
- the caspase-3 level is 94% higher compared to the control + KCI.
- the presence of chaperonins B and C have a regenerating effect similar to that induced by the medium + KCI.
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR112015020777A BR112015020777A2 (pt) | 2013-02-28 | 2013-12-30 | Métodos para prevenir a formação de oligômeros solúveis, estruturas pré-fibrilares, protofibrilares e de fibra e placas amiloides, para redução de efeito citotóxicos de estruturas beta-enoveladas e para proteção e regeneração in vitro e/ou in vivo de células |
US14/771,144 US9763900B2 (en) | 2013-02-28 | 2013-12-30 | Chemical chaperonins as novel molecular modulators of beta protein aggregation present in conformational diseases |
JP2015559419A JP6595345B2 (ja) | 2013-02-28 | 2013-12-30 | コンフォメーション病におけるβタンパク質凝集の新規の分子モジュレーターとしての化学シャペロニン |
CA2904762A CA2904762C (en) | 2013-02-28 | 2013-12-30 | Chemical chaperonins as new molecular modulator of the beta protein aggregation in conformational disease |
ZA2015/06583A ZA201506583B (en) | 2013-02-28 | 2015-09-07 | Chemical chaperonins as novel molecular modulators of beta protein aggregation present in conformational diseases |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU2013000027A CU20130027A7 (es) | 2013-02-28 | 2013-02-28 | Chaperoninas químicas como nuevos moduladores moleculares de la beta agregación proteica presente en las enfermedades conformacionales |
CU2013-0027 | 2013-02-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014131374A1 true WO2014131374A1 (es) | 2014-09-04 |
Family
ID=50114254
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CU2013/000009 WO2014131374A1 (es) | 2013-02-28 | 2013-12-30 | Chaperoninas químicas como nuevos moduladores moleculares de la beta agregación proteica presente en las enfermedades conformacionales |
Country Status (7)
Country | Link |
---|---|
US (1) | US9763900B2 (es) |
JP (1) | JP6595345B2 (es) |
BR (1) | BR112015020777A2 (es) |
CA (1) | CA2904762C (es) |
CU (1) | CU20130027A7 (es) |
WO (1) | WO2014131374A1 (es) |
ZA (1) | ZA201506583B (es) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104311443A (zh) * | 2014-09-27 | 2015-01-28 | 张远强 | 一类含萘环的丁二酸酰胺衍生物、其制备方法及用途 |
CN104311445A (zh) * | 2014-09-27 | 2015-01-28 | 张远强 | 含萘环的丁二酸酰胺衍生物、其制备方法及用途 |
CN104311441A (zh) * | 2014-09-27 | 2015-01-28 | 张远强 | 一类氯代萘环的丁二酸酰胺衍生物、其制备方法及用途 |
CN104311442A (zh) * | 2014-09-27 | 2015-01-28 | 张远强 | 卤代萘环的丁二酸酰胺衍生物、其制备方法及用途 |
CN104311444A (zh) * | 2014-09-27 | 2015-01-28 | 张远强 | 硝基取代萘环的丁二酸酰胺衍生物、其制备方法及用途 |
WO2022111742A1 (es) | 2020-11-24 | 2022-06-02 | Centro De Neurociencias De Cuba | Composición farmacéutica de derivados de naftaleno como agentes terapéuticos multiblancos para el tratamiento de la enfermedad de alzheimer |
Citations (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5276059A (en) | 1992-07-10 | 1994-01-04 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibition of diseases associated with amyloid formation |
JPH072012A (ja) | 1993-06-14 | 1995-01-06 | Kazuhiko Koumi | ポップアップルーフを有する自動車 |
WO1997016194A1 (en) | 1995-11-02 | 1997-05-09 | Warner-Lambert Company | Naphthylazo inhibition of amyloidosis |
US5637571A (en) | 1993-05-28 | 1997-06-10 | Conpharm Ab | Use of lignan derivatives for the preparation of pharmaceutical compositions for the treatment of states of amyloidosis |
CA2240005A1 (en) | 1997-06-17 | 1998-12-17 | Afroditi Kapurniotu | Peptides acting as agonists and inhibitors of amyloid formation and cytotoxicity for therapeutic use with alzeheimer's disease, type ii diabetes mellitus and spongiform encephalopathies |
US5869469A (en) | 1997-08-18 | 1999-02-09 | Queen's University At Kingston | Phosphonocarboxylate compounds for treating amyloidosis |
US6133259A (en) | 1994-07-19 | 2000-10-17 | University Of Pittsburgh | Alkyl, alkenyl and alkynyl chrysamine G derivatives for inhibition of cell degeneration and toxicity associated with amyloid deposition |
US20010047032A1 (en) | 1999-12-30 | 2001-11-29 | Castillo Gerardo M. | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases |
WO2002000603A1 (en) | 2000-06-23 | 2002-01-03 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Use of pamoic acid or one of its derivatives, or one of its analogues, for the preparation of a medicament for the treatment of diseases characterised by deposits of amyloid aggregates |
WO2003018070A1 (en) | 2001-08-27 | 2003-03-06 | The Trustees Of The University Of Pennsylvania | Stilbene derivatives and their use for binding and imaging amyloid plaques |
WO2003063880A1 (en) | 2002-01-29 | 2003-08-07 | Protemix Corporation Limited | Disruption of islet amyloid by polycyclic compounds |
WO2006066104A2 (en) | 2004-12-17 | 2006-06-22 | The Trustees Of The University Of Pennsylvania | Stilbene derivatives and their use for binding and imaging amyloid plaques |
US20070015737A1 (en) | 1999-07-09 | 2007-01-18 | Neurochem (International) Limited | Compounds for inhibiting diseases and preparing cells for transplantation |
WO2007045593A2 (en) | 2005-10-18 | 2007-04-26 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Naphthyl derivatives as inhibitors of beta-amyloid aggregation |
US20070155955A1 (en) | 2003-03-18 | 2007-07-05 | Applied Research Systems Ars Holding N.V. | Amylin aggregation inhibitors and use thereof |
WO2010111870A1 (zh) | 2009-04-03 | 2010-10-07 | Xu Weixuan | 硬币自动识别分币装置 |
WO2010118706A2 (es) | 2009-04-17 | 2010-10-21 | Centro De Neurociencias De Cuba | Procedimiento de obtención de nuevos derivados de naftaleno para el diagnóstico in vivo de la enfermedad de alzheimer |
US8106045B2 (en) | 2004-09-09 | 2012-01-31 | Mitsubishi Tanabe Pharma Corporation | 2-morpholino-4-pyrimidone compound |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
-
2013
- 2013-02-28 CU CU2013000027A patent/CU20130027A7/es unknown
- 2013-12-30 WO PCT/CU2013/000009 patent/WO2014131374A1/es active Application Filing
- 2013-12-30 BR BR112015020777A patent/BR112015020777A2/pt not_active IP Right Cessation
- 2013-12-30 JP JP2015559419A patent/JP6595345B2/ja not_active Expired - Fee Related
- 2013-12-30 US US14/771,144 patent/US9763900B2/en active Active
- 2013-12-30 CA CA2904762A patent/CA2904762C/en active Active
-
2015
- 2015-09-07 ZA ZA2015/06583A patent/ZA201506583B/en unknown
Patent Citations (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5276059A (en) | 1992-07-10 | 1994-01-04 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibition of diseases associated with amyloid formation |
US5637571A (en) | 1993-05-28 | 1997-06-10 | Conpharm Ab | Use of lignan derivatives for the preparation of pharmaceutical compositions for the treatment of states of amyloidosis |
JPH072012A (ja) | 1993-06-14 | 1995-01-06 | Kazuhiko Koumi | ポップアップルーフを有する自動車 |
US6133259A (en) | 1994-07-19 | 2000-10-17 | University Of Pittsburgh | Alkyl, alkenyl and alkynyl chrysamine G derivatives for inhibition of cell degeneration and toxicity associated with amyloid deposition |
WO1997016194A1 (en) | 1995-11-02 | 1997-05-09 | Warner-Lambert Company | Naphthylazo inhibition of amyloidosis |
US5955472A (en) * | 1995-11-02 | 1999-09-21 | Warner-Lambert Company | Naphthylazo inhibition of amyloidosis |
CA2240005A1 (en) | 1997-06-17 | 1998-12-17 | Afroditi Kapurniotu | Peptides acting as agonists and inhibitors of amyloid formation and cytotoxicity for therapeutic use with alzeheimer's disease, type ii diabetes mellitus and spongiform encephalopathies |
US5869469A (en) | 1997-08-18 | 1999-02-09 | Queen's University At Kingston | Phosphonocarboxylate compounds for treating amyloidosis |
US20070015737A1 (en) | 1999-07-09 | 2007-01-18 | Neurochem (International) Limited | Compounds for inhibiting diseases and preparing cells for transplantation |
US20010047032A1 (en) | 1999-12-30 | 2001-11-29 | Castillo Gerardo M. | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases |
WO2002000603A1 (en) | 2000-06-23 | 2002-01-03 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Use of pamoic acid or one of its derivatives, or one of its analogues, for the preparation of a medicament for the treatment of diseases characterised by deposits of amyloid aggregates |
WO2003018070A1 (en) | 2001-08-27 | 2003-03-06 | The Trustees Of The University Of Pennsylvania | Stilbene derivatives and their use for binding and imaging amyloid plaques |
WO2003063880A1 (en) | 2002-01-29 | 2003-08-07 | Protemix Corporation Limited | Disruption of islet amyloid by polycyclic compounds |
US20070155955A1 (en) | 2003-03-18 | 2007-07-05 | Applied Research Systems Ars Holding N.V. | Amylin aggregation inhibitors and use thereof |
US8106045B2 (en) | 2004-09-09 | 2012-01-31 | Mitsubishi Tanabe Pharma Corporation | 2-morpholino-4-pyrimidone compound |
WO2006066104A2 (en) | 2004-12-17 | 2006-06-22 | The Trustees Of The University Of Pennsylvania | Stilbene derivatives and their use for binding and imaging amyloid plaques |
WO2007045593A2 (en) | 2005-10-18 | 2007-04-26 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Naphthyl derivatives as inhibitors of beta-amyloid aggregation |
US20080255232A1 (en) * | 2005-10-18 | 2008-10-16 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Naphthyl Derivatives as Inhibitors of Beta-Amyloid Aggregation |
WO2010111870A1 (zh) | 2009-04-03 | 2010-10-07 | Xu Weixuan | 硬币自动识别分币装置 |
WO2010118706A2 (es) | 2009-04-17 | 2010-10-21 | Centro De Neurociencias De Cuba | Procedimiento de obtención de nuevos derivados de naftaleno para el diagnóstico in vivo de la enfermedad de alzheimer |
EP2436666A2 (en) | 2009-04-17 | 2012-04-04 | Centro De Neurociencias De Cuba | Method for obtaining novel derivatives of naphtalene for the in vivo diagnosis of alzheimer 's disease |
US20120321560A1 (en) * | 2009-04-17 | 2012-12-20 | Carrazana Marquiza Sablon | Method for Obtaining Novel Derivatives of Naphthalene for the In Vivo Diagnosis of Alzheimer's Disease |
Non-Patent Citations (82)
Title |
---|
AGDEPPA E. D., NEUROSCIENCES, vol. 117, 2003, pages 723 - 730 |
BARRIO JR, J. NUTR. HEALTH AGING., vol. 12, no. 1, 2008, pages 61S - 65S |
BENITEZ, A.; MORÁN J., J. NEUROSCI RES., vol. 71, 2003, pages 383 - 96 |
BENJAMIN I; MCMILLAN DR, CIRC. RES., vol. 83, 1998, pages 117 - 32 |
BLANCAS, S.; MORAN, J., J. NEUROCHEMISTRY INTERNATIONAL, vol. 58, 2011, pages 934 - 42 |
BRASKIE M.N., NEUROBIOL. AGING., vol. 31, no. 10, 2010, pages 1669 - 1678 |
BREITNER J.C.S., NEUROBIOL AGING., vol. 16, 1995, pages 523 - 530 |
BUCCIANTINI M., NATURE, vol. 416, 2002, pages 507 - 511 |
BURGEVIN, NEUROREPORT, vol. 5, 1994, pages 2429 |
BURROWS J. A. J., PROC NATL ACAD SCI USA, vol. 97, 2000, pages 1796 - 1801 |
BURROWS J. A. J., PROC. NATL. ACAD. SCI. USA, vol. 97, 2000, pages 1796 - 1801 |
CARRELL, LANCET, vol. 350, no. 9071, 1997, pages 134 - 138 |
CARRELL, R. W.; LOMAS, D. A., LANCET, vol. 350, 1997, pages 134 - 138 |
CHAPPLE J. P., TRENDS MOL MED., vol. 7, 2001, pages 414 - 421 |
CHAUDHURI, T. K.; P. SUBHANDAR, P., FEBS JOURNAL, vol. 273, 2006, pages 1331 - 1349 |
CHAUDHURI, T.; PAUL, S., FEBS JOURNAL, vol. 273, 2006, pages 1331 - 1349 |
CHILLARON, J. J., MED. CLIN. (BARC., vol. 130, no. 12, 2008, pages 466 - 470 |
CHITI, F.; DOBSON,C.M., ANNU. REV. BIOCHEM., vol. 75, 2006, pages 333 - 66 |
COHEN, F.; KELLY, J., NATURE, vol. 426, 2003, pages 905 - 909 |
FINDIES M. A., CURRO TOP MED. CHEM., vol. 2, 2002, pages 417 - 423 |
FRISARDI, V., AGEING RESEARCH REVIEWS, vol. 9, no. 4, 2010, pages 399 - 417 |
GAESTEL, M.: "Health And Disease, HEP", vol. 172, 2006, SPRINGER-VERLAG, article "Molecular Chaperones", pages: 1 - 42 |
GAGGELLI E., CHEM REV., vol. 106, 2006, pages 1995 - 2044 |
GALKIN O.; VEKILOV P. G., J. MOL. BIOL., vol. 336, 2004, pages 43 - 59 |
GONG, PROC. NATL. ACAD. SCI. USA, vol. 10, no. 18, 2003, pages 10417 - 22 |
HENRIKSEN G, EUR. J. NUCL. MED.MOL. IMAGING., vol. 35, no. 1, 2008, pages S75 - S81 |
HOOD, C. A., PEPT. SCI., vol. 14, 2008, pages 97 - 101 |
J. MORÁN, J. NEUROCHEM., vol. 73, 1999, pages 568 - 77 |
J. MORÁN, J. NEUROCHEM., vol. 73, no. 2, 1999, pages 568 - 77 |
KATES, E.; ALBERICIO, F.: "Solid-Phase Synthesis", 2000, MARCEL DEKKER INC. |
KORTH C., PROC. NATL. ACAD. SCI. USA, vol. 98, 2001, pages 9836 - 9841 |
KUNG, MOL. IMAGING BIOL., vol. 5, no. 6, 2003, pages 418 - 26 |
LIM G.P., J. NEUROSC., vol. 20, no. 15, 2001, pages 5709 - 5714 |
LIN H., BIOCHIM. BIOPHYS ACTA: MOL BASIS DIS., 2004, pages 1 - 10 |
LOO T. W.; CLARKE D. M., J. BIOL. CHEM., vol. 272, 1997, pages 709 - 712 |
LORENZO A., NATURE, vol. 368, 1994, pages 756 - 760 |
LORENZO A.; YANKER B. A., PROC. NATL. ACAD SCI., vol. 91, 1994, pages 12243 - 12247 |
LORENZO, NATURE, vol. 368, 1994, pages 756 - 760 |
LORENZO; YANKER, PROC. NATL. ACAD. SCI, vol. 91, 1994, pages 12243 |
LORENZO; YANKNER, PROC. NATL. ACAD. SCI., vol. 91, 1994, pages 12243 - 12247 |
MAY B. C., PROC. NATL. ACAD. SCI. USA, vol. 100, 2003, pages 3416 - 3421 |
MOGK, A., EMBO J., vol. 18, 1999, pages 6934 - 6949 |
MORELLO J. P., TRENDS PHARMACOL SCI, vol. 21, 2000, pages 466 - 469 |
MORGAN, ENVIRONMENTAL HEALTH PERSPECTIVES, vol. 102, no. 2, 1994, pages 63 |
NICOLLS, M. R., CURRO ALZHEIMER RES., vol. 1, no. 1, 2004, pages 47 - 54 |
NISHIMURA, R., AM. J. KIDNEY DIS., vol. 42, no. 1, 2003, pages 117 - 124 |
NITIN K. PANDEY ET AL: "Fructose restrains fibrillogenesis in human serum albumin", INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, vol. 61, 1 October 2013 (2013-10-01), pages 424 - 432, XP055105861, ISSN: 0141-8130, DOI: 10.1016/j.ijbiomac.2013.08.006 * |
O'BRIEN T. D., AM. J. PATHOL., vol. 147, 1995, pages 609 - 616 |
PAMBIANCO, G., DIABETES, vol. 55, no. 5, 2006, pages 1463 - 1469 |
PIKE CH. J., BRAIN RES., vol. 563, 1991, pages 311 - 314 |
PIKE, BRAIN RES., vol. 563, 1991, pages 311 - 314 |
POLLACK, NEUROSCIENCE LETTERS, vol. 184, 1995, pages 113 |
POLLACK, NEUROSCIENCE LETTERS, vol. 197, 1995, pages 21 1 |
PROFENNO, L., BIOL. PSYCHIATRY, vol. 67, 2010, pages 505 - 512 |
REIBEKAS A. A.; MASSEY V., J BIOL CHEM., vol. 272, 1997, pages 22248 - 22252 |
ROGERS J., NEUROLOGY, vol. 43, 1993, pages 1609 - 1611 |
SÁNCHEZ, Y., J. BACTERIOL., vol. 175, 1993, pages 6484 - 6491 |
SATO S., J. BIOL. CHEM., vol. 271, 1996, pages 635 - 638 |
SAWKAR A. R., PROC. NATL. ACAD. SCI. USA, vol. 99, 2002, pages 15428 - 15433 |
SCHIRMER E. C., TRENDS BIOCHEM SCI., vol. 21, 1996, pages 289 - 296 |
SCHUBERT, D., PROC. NATL. ACAD. SCI. USA, vol. 92, 1995, pages 1989 - 1993 |
SCHUBERT, PROC. NATL. ACAD. SCI. USA, vol. 92, 1995, pages 1989 - 1993 |
SEONG, 1. S., FEBS LETT., vol. 477, 2000, pages 224 - 229 |
SHOGHI-JADID K, AM. J. GERIATR. PSYCHIATRY., vol. 10, 2002, pages 24 - 35 |
STEWART W. F., NEUROLOGY, vol. 48, 1997, pages 626 - 632 |
SURGUCHEV, A SURGUCHOV, A. BRAIN RES BULL, vol. 81, 2010, pages 12 - 24 |
TAMARAPPOO B. K.; VERKMAN A. S., J CLIN. LNVEST., vol. 101, 1999, pages 2257 - 2267 |
TAMARAPPOO B. K.; VERKMAN A. S., J. CLIN. INVEST., vol. 101, 1999, pages 2257 - 2267 |
TUBIS, J. AMER. PHARM. ASSN., vol. 49, 1960, pages 422 |
VOGTHERR M., J. MED. CHEM., vol. 46, 2003, pages 3563 - 3564 |
WALSH D. M.; SELKOE D.J., J NEUROCHEM, vol. 101, 2007, pages 1172 - 84 |
YANG D. S., AMYLOID, vol. 8, 2001, pages 10 - 19 |
YANG F., J. BIOL. CHEM., vol. 280, 2005, pages 5892 - 5901 |
YANG, F., J. BIOL. CHEM., vol. 280, 2005, pages 5892 - 5901 |
YANKER B. A., SCIENCE, vol. 250, 1990, pages 279 - 282 |
YANKNER, SCIENCE, vol. 250, 1990, pages 279 - 282 |
YOSHIDA H., NEUROBIOL DIS., vol. 10, 2002, pages 88 - 99 |
YOSHIDA H., NEUROBIOL. DIS., October 2002 (2002-10-01), pages 88 - 99 |
ZAHN R., J. MOL BIOL., vol. 261, 1996, pages 43 - 61 |
ZEROVNIK, E., CURRENT ALZHEIMER RESEARCH, vol. 7, 2010, pages 74 - 83 |
ZHAO, W-Q; TOWNSEND, M., BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1792, 2009, pages 482 - 496 |
ZHUANG, J. MED. CHEM., vol. 44, no. 12, 2001, pages 1905 - 14 |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104311443A (zh) * | 2014-09-27 | 2015-01-28 | 张远强 | 一类含萘环的丁二酸酰胺衍生物、其制备方法及用途 |
CN104311445A (zh) * | 2014-09-27 | 2015-01-28 | 张远强 | 含萘环的丁二酸酰胺衍生物、其制备方法及用途 |
CN104311441A (zh) * | 2014-09-27 | 2015-01-28 | 张远强 | 一类氯代萘环的丁二酸酰胺衍生物、其制备方法及用途 |
CN104311442A (zh) * | 2014-09-27 | 2015-01-28 | 张远强 | 卤代萘环的丁二酸酰胺衍生物、其制备方法及用途 |
CN104311444A (zh) * | 2014-09-27 | 2015-01-28 | 张远强 | 硝基取代萘环的丁二酸酰胺衍生物、其制备方法及用途 |
CN104311443B (zh) * | 2014-09-27 | 2016-03-09 | 张远强 | 一类含萘环的丁二酸酰胺衍生物、其制备方法及用途 |
CN104311442B (zh) * | 2014-09-27 | 2016-04-06 | 张远强 | 卤代萘环的丁二酸酰胺衍生物、其制备方法及用途 |
CN104311445B (zh) * | 2014-09-27 | 2016-04-13 | 张远强 | 含萘环的丁二酸酰胺衍生物、其制备方法及用途 |
CN104311444B (zh) * | 2014-09-27 | 2016-05-18 | 张远强 | 硝基取代萘环的丁二酸酰胺衍生物、其制备方法及用途 |
WO2022111742A1 (es) | 2020-11-24 | 2022-06-02 | Centro De Neurociencias De Cuba | Composición farmacéutica de derivados de naftaleno como agentes terapéuticos multiblancos para el tratamiento de la enfermedad de alzheimer |
Also Published As
Publication number | Publication date |
---|---|
BR112015020777A2 (pt) | 2017-08-22 |
CA2904762C (en) | 2021-07-27 |
CU20130027A7 (es) | 2014-10-30 |
US9763900B2 (en) | 2017-09-19 |
CA2904762A1 (en) | 2014-09-04 |
ZA201506583B (en) | 2019-07-31 |
JP2016510007A (ja) | 2016-04-04 |
US20160106691A1 (en) | 2016-04-21 |
JP6595345B2 (ja) | 2019-10-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014131374A1 (es) | Chaperoninas químicas como nuevos moduladores moleculares de la beta agregación proteica presente en las enfermedades conformacionales | |
Kaushik et al. | The coming of age of chaperone-mediated autophagy | |
EP2673266B1 (en) | Phenothiazine diaminium salts and their use | |
Wong et al. | A safe, blood-brain barrier permeable triphenylmethane dye inhibits amyloid-β neurotoxicity by generating nontoxic aggregates | |
Igartúa et al. | Combined therapy for alzheimer’s disease: tacrine and PAMAM dendrimers co-administration reduces the side effects of the drug without modifying its activity | |
WO2017117430A1 (en) | Regulators of the endoplasmic reticulum proteostasis network | |
Pradhan et al. | Antiamyloidogenic chemical/biochemical-based designed nanoparticle as artificial chaperone for efficient inhibition of protein aggregation | |
RU2764131C2 (ru) | Водорастворимые производные 3,5-дифенилдиазольных соединений | |
Maity et al. | Peptidomimetic-based vesicles inhibit amyloid-β fibrillation and attenuate cytotoxicity | |
Belostozky et al. | Inhibition of tau-derived hexapeptide aggregation and toxicity by a self-assembled cyclic d, l-α-peptide conformational inhibitor | |
Radbakhsh et al. | Curcumin: A small molecule with big functionality against amyloid aggregation in neurodegenerative diseases and type 2 diabetes | |
Mitra et al. | Sequence and structure-based peptides as potent amyloid inhibitors: A review | |
Eleuteri et al. | Novel therapeutic strategy for neurodegeneration by blocking Aβ seeding mediated aggregation in models of Alzheimer's disease | |
WO2009047728A2 (en) | New s-acyl-glutathione derivatives, their syntesis and use in the treatment of oxidative stress-related diseases | |
Malishev et al. | Interactions between BIM protein and beta-amyloid may reveal a crucial missing link between Alzheimer’s disease and neuronal cell death | |
AU2015298491A1 (en) | Modulators of caspase-6 | |
US20140256625A1 (en) | Anti-amyloidogenic, alpha-helix breaking ultra-small peptide therapeutics | |
Ali et al. | Multiple Actions of H2S-Releasing Peptides in Human β-Amyloid Expressing C. elegans | |
WO2021180655A1 (en) | 2,5- or 2,6-disubstituted hydroquinone derivatives with at least one carboxy, sulfo or amido group useful as medicaments | |
ES2449640B1 (es) | Compuestos para su uso en el tratamiento de la enfermedad de alzheimer | |
KR102671166B1 (ko) | 3,5-디페닐-디아졸 화합물의 수용성 유도체 | |
WO2011095668A1 (es) | Uso de la yesotoxina, análogos y derivados para el tratamiento y/o la prevención de enfermedades neurodegenerativas relacionadas con tau y b-amiloide | |
Adeniji | Structure activity relationship (SAR) studies of a novel γ-secretase inhibitor | |
Gutekunst et al. | 11 Huntington’s Disease | |
Jakhria | Amyloid fibrils are nanoparticles that target lysosomes. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13830079 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2015559419 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2015/011275 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2904762 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013830079 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14771144 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112015020777 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112015020777 Country of ref document: BR Kind code of ref document: A2 Effective date: 20150827 |